Employee and Employer Benefits From a Migraine Management Program: Disease Outcomes and Cost Analysis

被引:8
|
作者
Schaetz, Leonhard [1 ]
Rimner, Timo [2 ]
Pathak, Purnima [3 ]
Fang, Juanzhi [4 ]
Chandrasekhar, Deepak [5 ]
Mueller, Jelena [1 ]
Sandor, Peter S. [6 ,7 ]
Gantenbein, Andreas R. [6 ,7 ]
机构
[1] Novartis Pharma AG, Basel, Switzerland
[2] Medgate, Basel, Switzerland
[3] Novartis Ireland Ltd, Dublin, Ireland
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Healint Pte Ltd, Singapore, Singapore
[6] RehaClinic, Neurol & Neurorehabil, Bad Zurzach, Switzerland
[7] Univ Hosp Zurich, Dept Neurol, Zurich, Switzerland
来源
HEADACHE | 2020年 / 60卷 / 09期
关键词
migraine; disease management program; Migraine Disability Assessment; Patient Activation Measure; participants' satisfaction; return on investment; WORK PRODUCTIVITY; HEADACHE; IMPACT; BURDEN; EPIDEMIOLOGY; DISABILITY; DISORDERS; RETURN;
D O I
10.1111/head.13933
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To assess the impact of a migraine management program offered as a complimentary service by a company within its corporate well-being program. Background Migraine imposes a substantial burden on patients, families, employers, and societies. As migraine primarily affects working-age adults, this has important implications for both employees and employers. Workplace educational and well-being programs positively contribute to employees' productivity, reduce costs related to absenteeism, and improve the quality of life of the employees living with migraine. Methods This was a non-interventional cohort study, which followed employees and their family members over time. Participants received 1 telemedicine consultation to determine migraine diagnosis or a high probability of having migraine and 6 sessions of individualized telecoaching from a specialized nurse via a specially developed smartphone application to optimize their migraine management leveraging all appropriate medical and lifestyle options. Participants were evaluated during the program and at 3 months after completion through a series of validated questionnaires including Migraine Disability Assessment (MIDAS), Patient Activation Measure (PAM), and satisfaction with the services offered. A cost analysis was also performed to determine the economic benefit of the program considering the number of completers, dropouts, their associated program costs, MIDAS data, average salary of a Swiss employee in the pharma sector, and working days per year. Results Of the 141 participants enrolled in the program, 79 completed 6-month and 42 completed 9-month assessments. The total MIDAS scores (mean, standard deviation [SD]) significantly improved from baseline by 54% at Month 6 (15.0 [13.6] vs 6.9 [8.2]; mean [SD] reduction: 8.1 [12.9], 95% confidence interval [CI]: 5.6-10.6;P < .0001) and by 64% at Month 9 (15.4 [14.7] vs 5.6 [6.0]; mean [SD] reduction: 9.8 [14.0], 95% CI: 6.6-13.0;P < .0001). The PAM scores also significantly improved from baseline by 8% at Month 6 (63.8 [10.9] vs 69.6 [12.8]; mean [SD] increase: 5.8 [12.8], 95% CI: 3.2-8.4;P = .003) and 11% at Month 9 (63.5 [10.7] vs 71.3 [12.2]; mean [SD] increase: 7.8 [11.0], 95% CI: 4.3-11.2;P = .003). At Month 6, common coaching lessons and respective action plans focused on progressive muscle relaxation, sleep, hydration, nutrition, general disease education, and stress management. The exit survey showed that the majority of the participants who completed the program had a meaningful and sustained improvement in their overall health and reported a high level of satisfaction with the program. The cost analysis revealed that on average participants gained 10.8 (95% CI: 9.3-12.3) working days/year that were previously lost due to migraine, resulting in a positive return on investment (ROI) of 490% (95% CI: 410%-570%), indicating a higher magnitude of savings that could be achieved by the implementation of such program. In addition to ROI and work productivity gained, participants also gained on average 13.6 (95% CI: 9.9-17.3) migraine-free days/year for their private and social life. Conclusion The employer-sponsored disease management program provided a better understanding of migraine, promoted methods and approaches to improve management by combining medical and lifestyle options leading to significant improvements in migraine symptoms that sustained beyond the intervention, supporting prolonged effectiveness of such programs. The program also provided a high ROI to the employer, supporting that the systematic inclusion of such programs into corporate well-being initiatives can be of significant benefit not only to the impacted individuals but to the employers as well.
引用
收藏
页码:1947 / 1960
页数:14
相关论文
共 50 条
  • [21] Stakeholder Perspective The Lessons from Delaware's Employee Benefits Program
    Vogenberg, F. Randy
    AMERICAN HEALTH AND DRUG BENEFITS, 2008, 1 (07): : 15 - 16
  • [22] Community Pharmacists' Impact on an Employer-Initiated Diabetes Disease Management Program
    Sansgiry, Sujit S.
    Agrawal, Ruchika N.
    Patel, Harshali K.
    Mhatre, Shivani K.
    Hayes, J. David
    Roberson, Kim
    James, Clyde J.
    JOURNAL OF PHARMACY TECHNOLOGY, 2012, 28 (02) : 68 - 74
  • [23] Employer-based diabetes disease management: assessing the health outcome and economic benefits
    Marquess, J.
    Valentine, W.
    Cobden, D.
    Palmer, A.
    Roze, S.
    DIABETOLOGIA, 2006, 49 : 554 - 555
  • [24] Innovation and skills from a sectoral perspective: a linked employer-employee analysis
    Schneider, Lutz
    Guenther, Jutta
    Brandenburg, Bianca
    ECONOMICS OF INNOVATION AND NEW TECHNOLOGY, 2010, 19 (02) : 185 - 202
  • [25] COST-EFFECTIVENESS ANALYSIS OF DISEASE MANAGEMENT PROGRAM OF HYPERTENSION IN SHANGHAI, CHINA
    Hu, S.
    VALUE IN HEALTH, 2010, 13 (07) : A522 - A522
  • [26] International Trade and Collective Bargaining Outcomes: Evidence from German Employer-Employee Data
    Felbermayr, Gabriel
    Hauptmann, Andreas
    Schmerer, Hans-Joerg
    SCANDINAVIAN JOURNAL OF ECONOMICS, 2014, 116 (03): : 820 - 837
  • [27] An integrated solution for employee cardiovascular disease management program in social community
    Chen, Weiwei
    Liu, Hua
    Luo, Ying
    He, Xinye
    Zhu, Manlu
    CARDIOLOGY, 2013, 126 : 4 - 4
  • [28] Assessing and reporting outcomes of a disease management program
    Johnson, N
    FORMULARY, 1999, 34 (05) : 455 - +
  • [29] Outcomes of an asthma disease management program.
    Ross, SJ
    Togger, DM
    Joos, TH
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 103 (01) : S71 - S71
  • [30] Disease management program improves asthma outcomes
    Jowers, JR
    Schwartz, AL
    Tinkelman, DG
    Reed, KE
    Corsello, PR
    Mazzei, AA
    Bender, DR
    Lochhead, RA
    AMERICAN JOURNAL OF MANAGED CARE, 2000, 6 (05): : 585 - 592